MB07133 300mg/m2/day
HCC-101
Phase 2 small_molecule completed
Quick answer
MB07133 300mg/m2/day for Hepatocellular Carcinoma is a Phase 2 program (small_molecule) at LIGAND PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- LIGAND PHARMACEUTICALS INC
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed